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Abstract: When Clostridium tetani was discovered and identified as a Gram-positive 
anaerobic bacterium of the genus Clostridium, the possibility of turning its toxin into a 
valuable biological carrier to ameliorate neurodegenerative processes was inconceivable. 
However, the non-toxic carboxy-terminal fragment of the tetanus toxin heavy chain 
(fragment C) can be retrogradely transported to the central nervous system; therefore, 
fragment C has been used as a valuable biological carrier of neurotrophic factors to 
ameliorate neurodegenerative processes. More recently, the neuroprotective properties  
of fragment C have also been described in vitro and in vivo, involving the activation of  
Akt kinase and extracellular signal-regulated kinase (ERK) signaling cascades through 
neurotrophin tyrosine kinase (Trk) receptors. Although the precise mechanism of the 
molecular internalization of fragment C in neuronal cells remains unknown, fragment C 
could be internalized and translocated into the neuronal cytosol through a clathrin-mediated 
pathway dependent on proteins, such as dynamin and AP-2. In this review, the origins, 
molecular properties and possible signaling pathways of fragment C are reviewed to 
understand the biochemical characteristics of its intracellular and synaptic transport. 
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1. Introduction 
The Clostridial neurotoxin family comprises tetanus neurotoxin and seven distinct botulinum 
neurotoxins, which cause the diseases tetanus and botulism [1,2]. Regarding neuroparalytic clostridia, 
Clostridial botulinum and Clostridial tetani produce the most potent toxins, botulinum and tetanus, 
due to their remarkable neurospecificity and their catalytic cleavage at low concentrations of neuronal 
substrates, which can oscillate between 10−12 and 10−13 M. The main difference between these toxins is 
in the intensity and duration of muscle paralysis. In fact, severe tetanus is characterized by violent and 
persistent spasms of the head, trunk and limb muscles [2]. 
The infectious nature of tetanus toxin was well documented before 1906, and the necessity of 
producing a tetanus antitoxin was decisive during the First World War [3]. The promising protective 
effects of eosin, tested in vitro and in vivo [4,5], and the development of serums against the toxin, 
mainly obtained in horses [6], undoubtedly opened a door to the unexplored field, at that time, of its 
molecular mechanism of action. In 1905, Sherrington described the mechanism of action of the toxin 
on spinal reflexes as a conversion of inhibition into excitation, thus destroying coordination [7]. 
Additionally, he investigated the effects of strychnine because this substance had a similar effect on 
the central nervous system as the tetanus toxin. In 1942, Acheson and collaborators concluded for the 
first time that the toxin was carried to the spinal cord through peripheral nerves when it was injected 
intramuscularly in cats; that is, the toxin traveled selectively through the segments of the spinal cord 
that supplied the innervation of the injected area [8]. Supporting this result, Brooks and collaborators, 
15 years later, studied the spinal inhibitory mechanisms based on five types of inhibition [9]: 
(a) direct inhibition of motoneurons by impulses in Group I a afferent fibers of antagonistic muscles; 
(b) inhibition by impulses in the Group I b afferent fibers from muscles of the same limb; 
(c) inhibition of extensor motoneurons by impulses in Groups II and III muscle afferent fibers and 
in cutaneous afferent fibers; and 
(d) inhibition of motoneurons following the activation of Renshaw cells by volleys in axon collaterals. 
These five forms of spinal inhibition were diminished and eventually abolished 8–10 h after 
injecting the toxin either peripherally into a mixed nerve trunk or directly into the spinal cord, which 
indicated that the toxin diffused slowly across the spinal cord, taking several hours to move 1 mm. 
From these results, it was also concluded that the toxin moved much faster longitudinally in nerve 
trunks and within the spinal cord [9]. 
The nature of the action of tetanus toxin has been widely described in different animal models [10–15], 
exploring its effect not only in the spinal cord but also in the cerebral cortex [16]. Different 
pharmacological substances have been used to ameliorate its symptoms in addition to eosin, such as 
acetylcholine and eserine [12]. These data were the starting point to attempt to characterize a protein 
that was completely necessary for the toxin to exert its effect, the tetanus-toxin receptor. Wassermann 
and Takaki, in 1898, observed that the toxin was fixed in the nervous tissue; in particular, brain tissue 
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was more effective than the spinal cord, and gray matter was more effective than white matter [17]. 
Eight years later, Landsteiner and Botteri believed that phrenosine was the receptor of the tetanus  
toxin [18]. However, in 1959 van Heyningen reinvestigated phrenosine as a possible receptor of  
the toxin, and he realized that the phrenosine concentrations in gray and white matter were inversely 
proportional to their capacity to fix the toxin. Based on his experiments in bovine brain samples, he 
concluded that the receptor was a highly specific substance that was mainly present in the gray matter, its 
interaction with the toxin was unaffected by temperature and it tended to associate with cerebrosides, 
although it was distinct from them [19,20]. Two years later, he confirmed that the sialic acid residues of 
the gangliosides were essential for toxin fixation and that the toxin did not appear to change the 
ganglioside molecule [21]. Although further studies supported this fact [22,23], currently, the identity 
of this receptor remains unknown despite knowledge of its agonist, tetanus toxin. 
2. Molecular Structure and Properties of Fragment C: Toward the Discovery of Fragment C 
Tetanus toxin is a single peptide of approximately 150 kDa, which consists of 1315 amino-acid 
residues. The toxin forms a two-chain activated molecule composed of a heavy chain (HC) and a light 
chain (LC) linked by a disulfide bond. The catalytic domain of the toxin resides in the LC, while the 
translocation and receptor-binding domains are present in HC [24–27] (Figure 1). Tetanus and 
botulinum toxins are zinc metalloproteases that cleave SNARE (soluble NSF attachment receptor) 
proteins, which interfere with the fusion of synaptic vesicles to the plasma membrane and ultimately 
blocks neurotransmitter release in nerve cells [28]. 
Figure 1. Diagram of the tetanus toxin molecule. The targeting and the translocation 
domains are located in the heavy-chain (HC), whereas the catalytic domain is located in the 
light-chain (LC) of the molecule. Its proteolytic activity is Zn2+-dependent, and heavy-metal 
chelators generate inactive apo-neurotoxins. The position of the cleavage of the tetanus-toxin 
molecule by papain is indicated. The digestion yields two fragments; one of them, fragment 
C, is approximately 50 kDa [29]. 
 
The mechanism of cell internalization and catalytic activity of tetanus toxin can be summarized in 
few steps [24,25] (Figure 2): 
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(a) cell binding, mainly mediated by the ganglioside-recognition domain in the C-terminal region  
of HC; 
(b) internalization into neuronal cells. Different internalization mechanisms have been described: 
the mechanism that tetanus toxin possibly follows to internalize into neurons may be a  
clathrin-mediated pathway, which is dependent on the proteins dynamin, AP-2 and AP180 [30]. 
Other potential receptor molecules will be discussed in the next section. 
(c) membrane translocation from mature endosomes into the neuronal cytoplasm. After incorporation 
of the toxin within endosomes, a structural change of the toxin is induced by the acidification of 
the endosomal environment; thus, a membrane-spanning pore forms. At this step, the 
oligomerization of four toxin amphipathic alpha-helices is required for channel formation; and 
(d) target recognition and catalytic cleavage of neuronal substrates. Once the toxin reaches the 
cytoplasm, it specifically cleaves neuronal proteins integral to vesicular trafficking and 
neurotransmitter release. In particular, the synaptic vesicle protein synaptobrevin (VAMP) is the 
target of tetanus toxin. This protein belongs to a family of proteins that facilitate exocytosis  
in neurons known as SNARE proteins. The other members of this family are syntaxin and 
SNAP-25, which are the main molecular targets of botulinum toxin. SNARE proteins are 
formed by coiled-coil interactions of the alpha-helices of its members, which is required for 
membrane fusion [31–33]. 
Figure 2. Proposed internalization pathway of tetanus toxin. The ganglioside-recognition 
domain in the C-terminal region of HC allows the toxin to be internalized into the neuron. 
The light chain of the toxin (LC) cleaves the soluble NSF attachment receptor (SNARE) 
complex, inhibiting neurotransmitter release. 
 
Botulinum toxins are produced by the anaerobic bacterium Clostridium botulinum, which is 
considered to be a potent blocker of synaptic transmission in peripheral cholinergic nervous system 
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synapses. There are seven serologically distinct botulinum isoforms (denoted A–G), which exhibit 
strong amino-acid sequence similarity. The mature toxin is characterized by three main structural 
domains, an N-terminal light chain Zn2+-metalloprotease and the heavy chain that contains the  
N-terminal, of approximately 50-kDa, translocation domain, and the C-terminal, of approximately  
50-kDa, receptor-binding domain. This receptor-binding domain comprises two subdomains, a β-sheet 
jelly-roll fold and a β-tree foil-fold carboxy subdomain. The seven botulinum toxin serotypes cleave 
specific residues on one of three SNARE proteins: botulinum serotypes B, D, F and G cleave VAMP, 
botulinum serotypes A and E cleave SNAP25, and botulinum serotype C cleaves SNAP25 and 
syntaxin 1a [26,28]. 
2.1. Molecular Properties of Fragment C 
2.1.1. Molecular Binding 
As previously mentioned, tetanus toxin can form channels in lipid membranes at low pH in the 
endosomal compartment of nerve cells. These channels are actually pores, which are involved in the 
transport of the toxin to the cytosol [34]. The ability to form pores in lipid vesicles resides in the 
hydrophobic domain of LC and the N-terminal of HC, which allows for the translocation of the toxin 
through the lipid membrane. However, in the absence of fragment C, the toxin retains little ability  
to paralyze neuromuscular transmission [35]. The lipids which are most sensitive to the action of  
the toxin are, in descending order: phosphatidylinositol > phosphatidylserine > phosphatidylcholine and 
cholesterol [36]. Furthermore, tetanus toxin increases its binding and insertion into lipid bilayer at acidic 
pH, suggesting that the toxin can penetrate into cells through a low pH intracellular compartment [37]. 
What is the molecular structure of fragment C that makes it essential for toxin behavior? 
The early step in tetanus-toxin internalization is cell binding. Lipid rafts are microdomains of the 
plasma membrane enriched in sphingolipids (gangliosides are members of this group of lipids), 
cholesterol and glycosylphosphatidylinositol (GPI)-anchored proteins. Lipid rafts behave as specialized 
domains for tetanus-toxin binding and internalization into neurons. In particular, gangliosides constitute 
the main part of mammalian plasma membranes. Their oligosaccharide residues and their ubiquity at the 
outer leaflet of the membrane allow them to function as bioactive signal transducers. The affinity of 
fragment C for gangliosides, which resides in the last 34 residues, has been widely tested in different 
animal models and in different tissues. For example, greater interaction was observed with long-chain 
gangliosides from rat brain than with similar gangliosides in rabbit kidney [38]. Furthermore, it is 
suggested that tetanus toxin, mainly through fragment C, and gangliosides undergo significant 
conformational changes upon their interaction, leading to the formation of macromolecular aggregates. 
In particular, cerebrosides, sulfatides, sphingomyelin and phosphatidylserine seem to increase the 
percentage of α-helices in the toxin [39]. 
Interestingly, studies on the ganglioside-binding properties of fragment C have demonstrated that 
polysialic acids within the gangliosides, such as GD1b (disialic acid residues attached to the internal 
galactose residue) and GT1b (disialic acid residues attached to the terminal galactose residue), but not 
GM1 (monosialic acid residue attached to the internal galactose residue), are necessary for the binding 
process [40,41]. Specifically, the amino-acid residues tryptophan 1288, histidine 1270 and aspartate 
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1221 were found to be critical for the binding of fragment C to ganglioside GT1b [42]. GT1b is a 
trisialo sphingolipid with a branched carbohydrate structure containing a single N-acetylneuraminic 
acid (NeuAc) on one arm and a NeuAc dimer on the other (Figure 3). The strongest and most specific 
ganglioside association with tetanus toxin is with GT1b because the targeting domain of the toxin contains 
two binding sites that can accommodate NeuAc residues separated by a distance of approximately  
25 Å [43]. Studies based on atomic-force microscopy/total internal-reflection fluorescence microscopy 
(TMAFM/TIRFM) reinforce this result, suggesting that the membrane activity of fragment C is dependent 
on both the ganglioside concentration in the membrane and the pH of the medium [44]. 
Figure 3. A schematic representation of the structures of gangliosides GT1b, GM1 and 
GD1b. The strongest and most specific ganglioside association with fragment C of tetanus 
toxin is with GT1b, since the targeting domain of the toxin contains two binding sites that 
can accommodate NeuAc residues. 
 
Additionally, the receptor-binding domain of tetanus and botulinum A and B toxins is structurally 
similar, containing two subdomains: an amino-terminal lectin-like jelly-roll subdomain and a  
carboxyl-terminal beta-trefoil subdomain linked by a single chain (Figure 4). Each of these 
subdomains is composed of beta-sheets joined by loops that protrude from the molecule. Regarding 
tetanus toxin, and based on previous studies [19–21,45], four distinct carbohydrate-binding sites for 
lactose, galactose, sialic acid and N-acetyl-galactosamine (NGA) were determined with X-ray 
crystallography [40,41]. In particular, the beta-trefoil subdomain seems to have a more relevant role in 
ganglioside binding than does the amino-terminal lectin-like subdomain, which was demonstrated by 
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analyzing the localization of these binding domains, showing that the binding function resided in the 
beta-trefoil domain [40,46] (Figure 4), and mutant proteins of fragment C [41]. 
Figure 4. (a) Image from the RCSB PD of PDB ID 1A8D [47]; (b) Illustration of the 
carbohydrate-binding sites for lactose (LAC), galactose (GAL), sialic acid (SIA) and  
N-acetyl-galactosamine (NGA) in tetanus toxin. These binding sites are localized in the 
beta-trefoil domain of fragment C (residues 865–1315). Adapted from [40]. 
(a) (b) 
Based on studies that included a combination of computational methods, these four  
carbohydrate-binding sites are localized in two different sites on the surface of fragment C: Site-1, a 
common site for all clostridial neurotoxins through which fragment C binds lactose and part of GT1b 
(Gal-GalNAc); and the other well-characterized site Site-2, through which fragment C binds 
sialyllactose, lactose, disialyllactose (DiSia), a tripeptide Tyr-Glu-Trp (YEW) and the Gal-NAc part of 
GT1b. Site-2 has been shown to be vital for the toxicity of the toxin [48]. Furthermore, Tyr 1290 and Trp 
1289 in Site-1 and Asp 1147 and Arg 1226 in Site-2 play a key role in ganglioside binding [49] (Figure 5). 
In particular, DiSia binding characterizes ganglioside binding to fragment C and could be the 
binding site for the ganglioside sugar moiety GD3 [48,50]. If ligands that simultaneously bind to two 
adjacent sites are identified, they could be used to develop bi-dentate reagents for tetanus toxin, as 
demonstrated by Cosman and collaborators. Of the six small molecules they studied, three were found 
to be the best ligands to use for preparing bi-dentate detection agents: doxorubicin or 3'-sialyllactose 
(binding to Site-1), lavendustin A, YEW and MP-biocytin (binding to Site-2) and the peptide  
Ser-Gln-Asn-Tyr-Pro-Ile-Val (SQNYPIV) (binding to a third independent site). Doxorubicin presents 
more advantages than do the other molecules because it tends to bind fragment C over a wider range of 
temperatures, solvent conditions and concentrations [50]. 
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Figure 5. (a) Image from the RCSB PDB of PDB ID 1FV3 regarding  
Site-1 of fragment C [51]; (b) Image from the RCSB PDB of PDB ID 1YYN regarding 
Site-2 of fragment C [52]. 
 
(a) (b) 
More recent studies have suggested that gangliosides are functional dual receptors for tetanus toxin 
and they are necessary for high-affinity binding to neuronal and non-neuronal cells. In particular, these 
studies showed that HC of the toxin bound gangliosides via two carbohydrate-binding sites, the lactose 
binding site called W-pocket and the sialic acid binding site called R-pocket. Both W- and R-pockets 
are the binding sites for GM1a and GD3 gangliosides [53]. 
Although the affinity of fragment C for gangliosides has been widely characterized, another 
hypothesis could suggest that a high-affinity protein receptor can be involved in tetanus toxin 
internalization. Schiavo and co-workers showed that the N-glycosylated 15-kD receptor protein has 
also been described as a surface glycoprotein that interacts with tetanus toxin in neuronal cell-lines and 
motor neurons. The C-terminal subdomain of fragment C of tetanus toxin is sufficient and necessary 
for cell binding and interaction with the 15-kD putative receptor, highlighting the importance of this 
domain of fragment C for the neurospecific interaction of the toxin [54]. The same group also suggested 
that GPI anchored protein Thy-1, a highly expressed glycoprotein that can interact with tetanus toxin to 
mimic ganglioside binding [55]. In addition, HC of the toxin can be retrograde-trafficked within motor 
neurons in Rab-7 positive structures that are shared with the neurotrophin receptors p75NRT and TrkB [56]. 
Swaminathan and co-workers showed that a tri-peptide Tyr-Glu-Trp bound to the binding-receptor domain 
of the toxin with interactions to Arg1226, suggesting that a protein as well as a ganglioside can bind to 
this domain [49]. 
Similarly to tetanus toxin, botulinum toxin Types A, B, C and F bind gangliosides GT1b, GD1b and 
GD1a, whereas botulinum Type E binds GT1b and GT1a, botulinum Type D binds 
phosphatidylethanolamine (PE) and botulinum Type G recognizes all the gangliosides with an 
approximately similar affinity [26]. Furthermore, the described surface-protein receptors, involved in 
neuronal specificity of botulinum toxins, are related to protein components of the synaptic vesicle 
membrane. Interestingly, the botulinum serotypes that exhibit highest sequence similarity share the 
same protein receptor. This is the case of botulinum Types A, E and F, which bind SV2, a family of 
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synaptic-vesicle membrane proteins, whereas botulinum Types B, and G bind SytI and SytII, which is 
the calcium sensor that triggers synaptic vesicle fusion. No protein receptor has been associated with 
botulinum Types C and D. The general pathway of nerve entry begins with the preinsertion conformation 
of the translocation domain, followed by the translocation of the light-chain protease across 
endosomes. This translocation is highly dependent on the pH gradient, redox gradient and the 
transmembrane potential. The completion of translocation ends when the C-terminus of the light chain 
enters the cytosol, where SNARE cleveage takes place and this is the last portion translocated that exit the 
channel. The disulfide bridge between light and heavy chains is crucial for botulinum toxicity and is 
required for chaperone function, acting as a principal determinant for cargo translocation and release [26]. 
2.1.2. Retrograde Axonal Transport 
One of the unique characteristics of tetanus toxin is that it can be transported retrogradely to the 
central nervous system from the circulatory system. The first question was whether fragment C itself 
could be transported by neurons similar to the native toxin while avoiding its toxicity. The trans-synaptic 
transport of fragment C was intensively studied in one of the best-characterized systems, the primary 
visual pathway [57,58], confirming its capacity as a carrier once it was injected intramuscularly [59]. 
Furthermore, the possibility of constructing hybrid molecules with fragment C has opened the door to an 
interesting research field, the discovery of neuro-anatomical tracers, whose main purpose is to map 
synaptic connections between neuronal cells. 
One of the most well-known hybrid proteins that has been used for this purpose is the hybrid 
protein encoded by lacZ-fragment C. This protein has been tested in vitro and in vivo to determine its 
activity in the hypoglossal system, and the detection of the labeled motor neurons was dependent on 
time post-injection [60–62]. Since neuronal integrity is crucial for fragment C internalization, the 
transneuronal molecular pathway at neuromuscular junctions was intensively studied using this hybrid 
protein [63]. The protein was detected not only in the neuromuscular junction postsynaptic side but 
also the soma of the motor neuron, away from the active zones in large uncoated vesicles (Figure 6). 
Other hybrid molecules form multicomponent proteins by recombining fragment C, the translocation 
domain of diphtheria toxin, and the DNA-binding fragment of the GAL4 transcription factor. This 
system was particularly effective in PC12 cells [64]. 
The advances in the understanding of these hybrid proteins have paved the way for new therapeutic 
approaches using fragment C as a carrier of neurotrophic factors to ameliorate the disease process of 
motor neuron diseases, neuropathies and pain. Moreover, fragment C represents a potential non-viral 
vector for delivering exogenous biomolecules, such as proteins and DNA, to neurons in vitro and  
in vivo [60]. Among the wide range of neurotrophic factors, such as nerve growth factor (NGF), 
neurotrophin-3, insulin-like growth factors and vascular epithelial growth factor, the factors most used 
to construct hybrid proteins with fragment C are brain-derived neurotrophic factor (BDNF) and  
glial-derived neurotrophic factor (GDNF). More recently, a novel multi-component nanoparticle 
system using polyethylene imine (PEI) has been evaluated to elicit the expression of BDNF in 
neuronal cell lines [65]. 
Int. J. Mol. Sci. 2012, 13 6892 
 
 
Figure 6. Proposed pathway for the hybrid protein β-Gal-fragment C. Once the hybrid 
protein is injected intramuscularly, it is found in large uncoated vesicles and then transported 
retrogradely to the endoplasmic reticulum (ER). Hypothetical pathways are indicated with 
dashed arrows. Adapted from [63]. 
 
Additionally, BDNF-fragment C and GDNF-fragment C hybrid proteins exert neuroprotective 
effects in vitro and in vivo. For example, GDNF-fragment C promotes neuronal survival and neurite 
outgrowth in animal models of Parkinson’s disease [66] and amyotrophic lateral sclerosis (ALS) [67,68], 
and BDNF-fragment C is protective in a mouse model of ALS, although no synergistic effect of this 
recombinant molecule was found [69]. 
Similarly, the hybrid protein that contains cardiotrophin-1 and fragment C promoted motor neuron 
survival in vitro in a dose-dependent manner [70], and the combination of the anti-apoptotic molecule 
Bcl-XL and fragment C improved cell survival and decreased apoptosis in the glutamate-mediated 
excitotoxicity of SH-SY5Y neuronal cells [71]. 
Furthermore, fragment C of tetanus toxin and NGF share the same retrograde transport organelles, 
suggesting neurotrophin receptor p75NTR as the first membrane marker of the retrograde endocytic 
pathway used by fragment C of tetanus toxin [72]. p75NTR is a transmembrane receptor for neurotrophic 
factors of the neurotrophin family, which comprises NGF, BDNF and neurotrophin-3 and -4/5. In 
addition to p75NTR, neurotrophins signal, via the tropomyosin-related kinase (Trk) family of receptors, 
tyrosine kinases Trk A, B and C. The two receptor systems can function synergistically, antagonistically 
or independently of each other in different cell types [73]. The retrograde pathway of fragment C of 
tetanus toxin is shared by p75NTR, TrkB and BDNF, which is strongly dependent on the activities of the 
small GTPases Rab5 and Rab7 [56], which suggest that at least a portion of p75NTR is transported toward 
the soma without undergoing proteolytic cleavage. In particular, an impairment of Rab7 activity inhibits 
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the trafficking of fragment C-, p75NTR- and TrkB-containing carriers. However, Rab7 impairment in 
PC12 cells led to an increase in TrkA and extracellular-regulated kinases (ERK-1/2) phosphorylation 
and the stimulation of NGF [56]. 
Considering the potential use of fragment C as a non-viral vector and its likely sharing a common 
molecular pathway as the one described for the neurotrophic factor BDNF [74], there is speculation 
about its possible neuroprotective properties. Does fragment C have neuroprotective properties? 
3. Possible Signaling Pathways for Fragment C of Tetanus Toxin 
The molecular pathway involving the activation of the Trk receptors is closely shared by 
neurotrophic factors and fragment C. The neurotrophin family has been shown to regulate survival, 
development and functional aspects of neurons in the central and peripheral nervous systems through 
the activation of one or more of the three members of the receptor tyrosine kinases (TrkA, TrkB, and 
TrkC) in cooperation with p75NTR [75,76]. NGF can bind to the TrkA receptor or a complex of TrkA 
and p75NTR [75], BDNF and neurotrophin-4/5 can bind to TrkB, and neurotrophin-3 binds to TrkC. 
Furthermore, similarly to the specialized internalization of fragment C in a clathrin-dependent process, 
Schiavo and co-workers proposed that NGF can trigger the recruitment of a pool of p75NTR to  
clathrin-coated pits to be delivered into the soma of motor neurons, which highlights the regulation of 
p75NTR signaling in response to neurotrophins [30,77]. In addition, p75NTR can also interact with  
pro-neurotrophins and, therefore, it serves as a signaling component of the receptor complex for  
growth-inhibitory molecules of CNS, such as Nogo, prompting Nogo receptor-mediated signaling [78,79]. 
Aguilera and co-workers described an increase in serotonin synthesis in the central nervous system 
induced by tetanus toxin, suggesting that the toxin-affected serotonergic innervation in the perinatal rat 
brain triggered the translocation of calcium-phosphatidylserine-dependent protein kinase C (PKC) [80].  
In particular, they found that tetanus toxin, but not botulinum toxin (BoNT/A), produced a specific 
time- and dose-dependent inhibition of serotonin uptake in rat central nervous system synaptosomes. 
In fact, tetanus toxin altered a component involving inositol phospholipid hydrolysis, which is 
associated with PKC activity translocation [81,82]. In addition to this translocation, an enhancement of 
the tyrosine phosphorylation of the tyrosine receptor TrkA, phospholipase C (PLCγ-1) and ERK-1/2 was 
also observed [83]. Because fragment C stimulated the PLC-mediated hydrolysis of phosphoinositides in 
rat brain neurons, this fragment appeared to modulate some signaling pathways involving the transport  
of serotonin [84]. 
Furthermore, the activation of intracellular pathways related to the PLCγ-1 phosphorylation and 
activation of PKC isoforms and the kinases Akt (at Ser 473 and Thr 308) and ERK-1/2 (at Thr 202/Tyr 
204) was induced by fragment C in rat brain synaptosomes and cultured cortical neurons. This signal 
pathway activation was dependent on time and concentration, suggesting that fragment C could exert 
neuroprotective effects, activating TrkA and TrkB receptors in a similar manner as do NGF and BDNF 
or neurotrophin-4/5 [85,86]. 
Fragment C also protected cerebellar granular cells against potassium deprivation-induced apoptotic 
death [87] and acted as a neuroprotector in a model of 1-methyl-4-phenylpyridinium (MPP+)-triggered 
apoptosis, enhancing the survival pathways in rats with a dopaminergic lesion and improving different 
motor behaviors. In this study, fragment C induced Ser 112 and Ser 136 BAD phosphorylation, 
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activated the transcription factor NF-κB, which prevents neuronal death, and induced a decrease in the 
release of cytochrome c and, consequently, a reduction in the activation of procaspase-3 and chromatin 
condensation [88,89] (Figure 7). 
Figure 7. Proposed signaling pathway for fragment C. Based on the results obtained by 
Aguilera and co-workers, fragment C can induce cerebellar granular cell survival under 
stress conditions, activating signaling pathways associated with Trk receptors that include 
the activation of PLC, the Ras/MAPK pathway and the PI3 pathway, leading to the 
survival of the cell [88,89]. Another possible retrograde pathway of fragment C of tetanus 
toxin is shared by p75NTR, TrkB and BDNF, which is strongly dependent on the activities 
of the small GTPases Rab5 and Rab7 [56]. 
 
Consequently, the main advantage of using fragment C as a potential therapeutic agent in non-viral 
gene therapy is particularly interesting in amyotrophic lateral sclerosis (ALS). The failure of standard 
treatments in ALS could rely on the inappropriate route of administration and/or the poor bioavailability 
of molecules to the target cell [90]. The subcutaneous and intrathecal delivery of neurotrophic factors 
can cause adverse side effects such as weight loss, fever, cough, fatigue and behavioral changes [91], 
whereas viral gene therapy based on the use of an adeno-associated virus or lentivirus vectors is more 
efficient than the neurotrophic factor delivery but can induce several inherent hazards [92]. An 
alternative strategy that effectively reaches motor neurons, can exert neuroprotective properties and 
does not show such adverse side effects implies the use of fragment C. Osta and co-workers found in a 
mouse model of ALS, which carries the mutation G93A in human superoxide dismutase 1 (SOD1), 
transgenic SOD1G93A mice, an amelioration of the decline in hind-limb muscle innervation in the animals 
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that were injected with either naked DNA-encoding fragment C (TTC) or naked DNA, encoding the 
recombinant molecule fragment C and BDNF (BDNF-TTC). In addition, a significant delay in the onset 
of symptoms and functional deficits, an improvement in the spinal motor neuron survival  
(down-regulation of caspase-1 and caspase-3 levels and a significant phosphorylation of serine/threonine 
protein kinase Akt) and a prolonged lifespan under both treatments was observed [69,93]. Although no 
significant differences were found between TTC and BDNF-TTC treatments, recombinant plasmid 
BDNF-TTC was detected in skeletal muscle and the corresponding recombinant protein reached the 
spinal cord tissue of transgenic SOD1G93A mice, reinforcing on the one hand the carrier properties of 
fragment C. The active state of BDNF in the recombinant molecule could suggest that BDNF could 
exert an autocrine and neuroprotective role together with TTC to a similar extent as TTC alone; 
however this effect could not be sufficient enough to prompt a synergistic effect. As a consequence, 
BDNF-TTC molecule could mainly use the same pathway that mimics a neurotrophic secretion route, 
prompting survival signals in the spinal cord of transgenic SOD1G93A mice [66]. 
Despite all these contributions to the understanding of the signaling pathway of fragment C, further 
studies should be performed to elucidate its neuroprotective effect. 
4. Conclusions 
Fragment C is considered to be a useful and valuable tool to carry therapeutic molecules due to its 
efficient retroaxonal transport. This is the main reason why this particular property has been exploited 
as a therapeutic strategy in the central nervous system to ameliorate the disease process of well-known 
neurodegenerative diseases, such as Parkinson’s and ALS. However, recent in vitro and in vivo studies 
have shown that fragment C can enhance cell survival by itself. This new property of fragment C has 
opened the door to the understanding of its possible, although not yet well-characterized, molecular 
pathways. Because the characterization of the protein-protein interaction at the molecular level is of 
high importance and the plasma membrane of each nervous cell contains a particular composition, a 
messenger, such as fragment C, can exert different effects depending on the signaling pathway it 
modulates, which is directly related to the type and distribution of different receptors in the plasma 
membrane. Thus, a messenger is not the molecule that carries the message; many results can be 
obtained when studying the same effector molecule under different experimental conditions. 
Regarding fragment C, new studies will reveal the precise molecular mechanism by which it can 
induce its neuroprotective properties. This mechanism could shed light on using fragment C as an 
alternative therapeutic strategy for more neurodegenerative diseases in the near future. 
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